Document Detail


IFN-α in the treatment of melanoma.
MedLine Citation:
PMID:  23042723     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Among the IFNs, IFN-α2 has been the most broadly evaluated clinically. At the molecular level, IFN-α has multiple effects in a variety of malignancies that range from antiangiogenic to potent immunoregulatory, differentiation-inducing, antiproliferative, and proapoptotic effects. A multitude of IFN-α2 regimens that may be classified as low dose, intermediate dose, and high dose have been evaluated as adjuvant therapy in melanoma. A durable impact on both relapse-free and overall survival was seen only with the regimen utilizing high-dose IFN-α2b tested in the Eastern Cooperative Oncology Group and intergroup trials E1684, E1690, and E1694 as adjuvant therapy for high-risk surgically resected melanoma (stage IIB or III). Adjuvant pegylated IFN-α2b has also been evaluated at maximally tolerable doses compared with the observation group in the European Organization for Research and Treatment of Cancer trial 18991 and has shown relapse-free survival benefits in patients with microscopic nodal disease.
Authors:
Ahmad A Tarhini; Helen Gogas; John M Kirkwood
Related Documents :
24057163 - High-sensitivity lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts ea...
24972773 - Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and...
25283313 - Improving timely detection and recording of colorectal peritoneal metastases.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of immunology (Baltimore, Md. : 1950)     Volume:  189     ISSN:  1550-6606     ISO Abbreviation:  J. Immunol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-08     Completed Date:  2012-12-18     Revised Date:  2014-03-10    
Medline Journal Info:
Nlm Unique ID:  2985117R     Medline TA:  J Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3789-93     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Dose-Response Relationship, Immunologic
Humans
Interferon-alpha / antagonists & inhibitors,  therapeutic use*
Melanoma / immunology*,  secondary,  therapy*
Meta-Analysis as Topic
Tumor Escape / immunology
United States
United States Food and Drug Administration
Grant Support
ID/Acronym/Agency:
P50 CA121973/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Interferon-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Equimolar CO(2) Capture by N-Substituted Amino Acid Salts and Subsequent Conversion.
Next Document:  A Galvanic Replacement Route to Prepare Strongly Fluorescent and Highly Stable Gold Nanodots for Cel...